Clinical Trials
33 trialsNCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT04700124 2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04109066 2025-01-08
CheckMate 7FL
Bristol-Myers Squibb
Phase 3 Completed
NCT06106568 2024-11-04
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
Bayer
Completed
NCT03493854 2024-06-26
FeDeriCa
Hoffmann-La Roche
Phase 3 Completed
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT04629846 2024-04-19
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02586025 2023-05-22
PEONY
Hoffmann-La Roche
Phase 3 Completed
NCT03916744 2023-03-10
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Completed
NCT04436744 2023-02-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Completed
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT00191126 2019-09-12
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Eli Lilly and Company
Phase 3 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT01142778 2018-03-16
AVATAXHER
Hoffmann-La Roche
Phase 2 Completed
NCT01444729 2017-10-26
Post Approval Commitment Study
Endo Pharmaceuticals
Completed
NCT00865189 2017-08-04
INOVA
Hoffmann-La Roche
Phase 2 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00024570 2014-11-14
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00849472 2014-03-04
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00191308 2011-10-21
Molecular Profiling in Lung Cancer Patients
Eli Lilly and Company
Phase 2 Completed
NCT00152217 2011-07-07
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00152230 2011-07-07
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00152243 2011-07-07
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00024557 2011-06-06
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Phase 1 Completed
NCT00041587 2011-06-06
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00064779 2011-06-06
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed
NCT00191789 2010-07-27
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00161980 2006-10-23
Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites
Baxter Healthcare Corporation
Phase 3 Completed